Optibrium and ChemAxon Announce Technology Collaboration
![](/46/pdcnewsitem/03/43/89/liI3iIT77qy2IFG.png)
Optibrium and ChemAxon, developers of software and cheminformatics solutions for drug discovery, have announced the results of a collaboration to integrate ChemAxon’s Plexus with Optibrium’s StarDrop software suite. The integration of these platforms further enables researchers to develop strategies for efficient, high quality compound library design.
The StarDrop software platform from Optibrium facilitates multi-parameter optimisation, property prediction and data visualisation to guide the design of high quality compounds for drug discovery projects. ChemAxon’s Plexus is a web-based collaborative discovery platform which enables scaffold- and reaction-based enumeration of compound libraries.
As a result of the collaboration, a seamlessly integrated workflow and user interface is available in StarDrop for the application of Plexus to enumerate compound libraries. These are returned as data sets within StarDrop for detailed analysis, visualisation and selection of compounds with an optimised balance of the properties required for success.
Matthew Segall, CEO of Optibrium, will provide an overview of the results of this collaboration at ChemAxon's European User Group Meeting being held in Budapest, Hungary, 19–20 May.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance